CR10780A - Inhibidores de cinasa - Google Patents

Inhibidores de cinasa

Info

Publication number
CR10780A
CR10780A CR10780A CR10780A CR10780A CR 10780 A CR10780 A CR 10780A CR 10780 A CR10780 A CR 10780A CR 10780 A CR10780 A CR 10780A CR 10780 A CR10780 A CR 10780A
Authority
CR
Costa Rica
Prior art keywords
compounds
kinase inhibitors
methods
intermediaries
kinases
Prior art date
Application number
CR10780A
Other languages
English (en)
Inventor
Qing Dong
Bheema PARASELLI
Jeffrey Alan Stafford
Michael B Wallace
Hasanthi Wijesekera
Jason W Brown
Original Assignee
Takeda San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/539,857 external-priority patent/US8119655B2/en
Application filed by Takeda San Diego Inc filed Critical Takeda San Diego Inc
Publication of CR10780A publication Critical patent/CR10780A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan compuestos para uso con las cinasas que comprenden un compuesto seleccionado del grupo que consiste de la formula (I) en donde las variables son como se definen en la presente. Tambien se proporcionan composiciones farmaceuticas, kits y articulos para manufactura que comprenden tales compuestos; metodos e intermediarios utiles para hacer los compuestos; y metodos de uso de los compuestos.
CR10780A 2006-10-09 2009-05-08 Inhibidores de cinasa CR10780A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/539,857 US8119655B2 (en) 2005-10-07 2006-10-09 Kinase inhibitors
PCT/US2006/039667 WO2007044779A1 (en) 2005-10-07 2006-10-10 Kinase inhibitors
US91262907P 2007-04-18 2007-04-18

Publications (1)

Publication Number Publication Date
CR10780A true CR10780A (es) 2009-06-05

Family

ID=40719252

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10780A CR10780A (es) 2006-10-09 2009-05-08 Inhibidores de cinasa

Country Status (9)

Country Link
EP (3) EP2079696A2 (es)
KR (1) KR20090068277A (es)
AU (1) AU2007313961A1 (es)
CA (1) CA2666138A1 (es)
CR (1) CR10780A (es)
DO (1) DOP2009000073A (es)
EC (1) ECSP099315A (es)
NO (1) NO20091817L (es)
WO (1) WO2008054956A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20110184178A1 (en) * 2008-04-16 2011-07-28 Takeda Pharmaceutical Company Limited Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
EP2283014A1 (en) * 2008-04-16 2011-02-16 Takeda Pharmaceutical Company Limited Polymorphs of hydrochloride salt o5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyridoý2,3-b¨indole-7-carboxamideand methods of use therefor
US20090312288A1 (en) * 2008-04-16 2009-12-17 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2009151598A1 (en) 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
CN112525878B (zh) * 2020-10-14 2023-05-16 辽宁石油化工大学 一种具有过滤功能sers基底的制备方法及应用
CN118027138A (zh) * 2022-11-07 2024-05-14 南京中澳转化医学研究院有限公司 吡啶酮类化合物及其制备方法、药物组合物和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
NZ584499A (en) * 2004-03-30 2011-08-26 Vertex Pharma Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases
FR2876377B1 (fr) * 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
EP1896472A1 (de) * 2005-06-09 2008-03-12 Boehringer Ingelheim International GmbH Alpha-carboline als cdk-1 inhibitoren
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010500961A (ja) * 2006-08-02 2010-01-14 武田薬品工業株式会社 α−カルボリン誘導体およびその製造方法

Also Published As

Publication number Publication date
AU2007313961A2 (en) 2009-06-11
EP2145877B1 (en) 2012-10-03
DOP2009000073A (es) 2018-02-28
EP2145877A3 (en) 2010-02-24
WO2008054956A3 (en) 2008-09-04
EP2145878A2 (en) 2010-01-20
ECSP099315A (es) 2009-06-30
AU2007313961A1 (en) 2008-05-08
EP2145877A2 (en) 2010-01-20
EP2079696A2 (en) 2009-07-22
NO20091817L (no) 2009-06-26
CA2666138A1 (en) 2008-05-08
EP2145878A3 (en) 2010-02-24
WO2008054956A2 (en) 2008-05-08
KR20090068277A (ko) 2009-06-25

Similar Documents

Publication Publication Date Title
CR10780A (es) Inhibidores de cinasa
CR11370A (es) Inhibidores de quinasas simil polo
CR10937A (es) Inhibidores de cinasa mapk/erk
CR20110135A (es) INHIBIDORES DE cMET
ECSP10010688A (es) Activadores de glucoquinasa
ECSP10010434A (es) Inhibidores de hsp90
NI201000198A (es) Compuestos triazina como inhibidores mtor y quinasa p13.
CU20110052A7 (es) Compuestos orgánicos
CU23840B1 (es) Nuevos derivados de sulfonamida como antagonistas de la bradiquinina
CR11492A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
CO6531451A2 (es) Compuesto de pirrolo[2,3-d]pirimidina
UY32077A (es) Inhibidores de quinasa tipo polo
UY32529A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintetasa quinasa 3
CR10818A (es) Inhibidores de cinasa mapk/erk
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735
WO2009129401A8 (en) Kinase inhibitors
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
NI201100035A (es) Agentes antifúngicos.
CO6331464A2 (es) Inhibidores de cinasa
ECSP099630A (es) Proceso e intermediarios para preparar arzoxifeno
UA99739C2 (ru) Ингибиторы polo-подобных киназ
CO6321260A2 (es) Derivados aromaticos de oxima como inhibidores de hsp90
DOP2009000085A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucogeno
UY29273A1 (es) Nuevos derivados de hidantoina, composiciones que los contienen, procesos de preparación y aplicaciones